Ask My Investor AI
Public company · NYSEPublished company research
LLY

Identity verified against SEC EDGAR filing 0000059478-26-000013; registered as ELI LILLY & Co, CIK 0000059478.

Eli Lilly and Company

Lilly has a genuine radioligand-therapy platform through its completed POINT Biopharma acquisition, internal discovery, partnerships, manufacturing capability and supply chain. However, Q1 2026 revenue of $19.799 billion was driven primarily by Mounjaro and Zepbound, and no radioligand revenue or profit is separately disclosed. Theme exposure is therefore strategic but financially unquantified, and the subject remains NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
LLY
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0000059478
Investment case

How this company captures the theme economics

Competitive position

Lilly states that it is building a comprehensive RLT portfolio using internal discovery, partnerships, a robust supply chain and manufacturing capabilities. POINT added a 180,000-square-foot radiopharmaceutical campus and clinical/preclinical assets. Current official disclosure does not establish a commercial radioligand franchise or standalone economics.

Scarce assets

Scarce assets in this value chain include actinium-225 global supply (~3 curies/year) and non-carrier-added separation capability, enriched targets and precursor feedstock (mo-98/mo-100, yb-176, ra-226/th-229) with few qualified suppliers, qualified reactor / cyclotron / accelerator irradiation slots and gmp linkage.

Products, segments, and customers

Lilly's reported growth is dominated by cardiometabolic medicines. Medical Isotopes exposure sits within oncology R&D through POINT Biopharma and other radioligand programs; the SPLASH PNT2002 trial remains sponsored by POINT as a wholly owned Lilly subsidiary, while commercial rights and development responsibilities require asset-level review.

Theme capture

Direct operating capability but diluted financial exposure. Official sources confirm POINT ownership, radioligand manufacturing and supply-chain capability, and an active RLT portfolio, but no theme-specific revenue, margin or valuation contribution is disclosed.

Conditions

What must be true

  1. Confirm current POINT/Aktis asset ownership and stage, clarify which Lu-177 programs Lilly retains, and watch for any dedicated radiopharma manufacturing investment.
  2. The exposure described for Eli Lilly must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Medical isotopes and radiopharmaceutical logistics brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Radiopharma pipeline: Lu-177 and next-generation assets via POINT Biopharma and Aktis Oncology.

Medical isotopes and radiopharmaceutical logistics

Strategic but financially diluted exposure. Official Lilly sources confirm completed ownership of POINT, a comprehensive RLT portfolio, manufacturing and supply-chain capability, and ongoing PNT2002 sponsorship. Q1 2026 reporting does not disclose radioligand revenue or profit.

Evidence
Lilly's acquisition release, current RLT overview, Q1 2026 results and ClinicalTrials.gov directly support corporate identity, operating capability, financial scale and ongoing PNT2002 sponsorship. Asset-level commercial rights and theme-specific economics remain unresolved.
Materiality
not assessed — Operating exposure is directly disclosed, but theme-specific financial materiality cannot be quantified within Lilly's $19.799 billion Q1 2026 revenue base.
Financial evidence

Official SEC filing evidence

Reference period: Q1 2026.

  • Revenue$19.799 billion, up 56% year over year
    Q1 2026[1]
  • Reported net income$7.396 billion
    Q1 2026[1]
  • Reported EPS$8.26
    Q1 2026[1]
  • Research and development expense$3.5 billion, or 18% of revenue
    Q1 2026[1]
  • 2026 revenue guidance$82.0 billion to $85.0 billion
    updated April 30, 2026[1]
  • POINT acquisition considerationapproximately $1.4 billion announced
    completed December 27, 2023[2]

Limitation: Official reporting establishes group scale, profitability and R&D spending. It does not disclose radioligand revenue, profit, isotope capacity, asset-level economics or a licensed current valuation.

Risks

Material risks and break conditions

Material risks

  • Clinical adoption disappoints or pivotal trials miss (e.g., PSMA therapy, SSTR/alpha-emitter programs), undercutting the demand leg.
  • Capacity for Lu-177/Ac-225/Mo-99 expands ahead of demand, normalizing prices and lead times and eroding scarcity-based pricing power.

Thesis-break conditions

  • Clinical adoption disappoints: flagship radioligand revenue growth stalls or pivotal Phase 3 trials fail, breaking the demand assumption.
  • Capacity expands far ahead of demand: Ac-225/Lu-177/Mo-99 additions (SHINE ~3/4 of US Mo-99, NorthStar ~40%, TerraPower ~20x Ac-225, Cardinal/BWXT expansions) drive spot isotope prices and lead times down and eliminate shortage conditions.
Investability conclusion

Where the evidence lands

Identity and filing financials are established; theme materiality is stated per the mapped theme assessment. This is a filing-backed research profile with deeper company-specific research pending, and is not a personalized recommendation.

Next diligence

  1. Confirm current POINT/Aktis asset ownership and stage, clarify which Lu-177 programs Lilly retains, and watch for any dedicated radiopharma manufacturing investment.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicinesEli Lilly and Company · primary · published 2026-04-30 · accessed 2026-07-29
  2. Lilly Completes Acquisition of POINT BiopharmaEli Lilly and Company · primary · published 2023-12-27 · accessed 2026-07-29
  3. Realizing the Potential of Radioligand TherapiesEli Lilly and Company · primary · published undated · accessed 2026-07-29
  4. SPLASH PNT2002 trial NCT04647526ClinicalTrials.gov / U.S. National Library of Medicine · primary · published 2026-01-13 · accessed 2026-07-29
  5. ELI LILLY & Co FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-12 · accessed 2026-07-22